monotherapy question, did appetite move for you without a GLP-1 alongside
#cagrilintide 2025-04-15
Tuesday21 messages5 participantstimes are UTC
Highlights from this day
- careful_claims — added it to an existing semaglutide dose rather than starting both, which made attribution possible 12:08
- careful_claims — two PeptideMeter results on the same WXT lot came back 99.4 and 99.2, closer than i expected 12:33
- careful_claims — is there a reason people titrate this over more weeks than the others 14:31
held mine a while
amylin not glp-1
added it to an existing semaglutide dose rather than starting both, which made attribution possible
🎉1❤️1⚠️10
quick one CagriSema is cagrilintide with semaglutide and REDEFINE is the trial programme around it
two PeptideMeter results on the same WXT lot came back 99.4 and 99.2, closer than i expected
[edited]the fullness effect hasnt faded over 4 months, unlike my semaglutide appetite curve
coming back to this dropped the GLP-1 and stayed on this alone for 9 months, appetite held but weight barely moved
separate days
REDEFINE is the phase 3 programme, most of what gets quoted casually in here is earlier work
amylin analogue, so its not a GLP-1 at all right
held at 2.5 for 4 months on monotherapy before i touched it again
anyone got two PeptideMeter results on the same TFC lot for this
stopped for 20 months and the fullness went within a fortnight of the last dose, thats one data point
if youre used to GLP-1 titration steps this feels absurdly cautious and i still do it that way
the combination is the thing with trial data behind it, monotherapy in here is mostly us guessing
quick one how do people separate which of the two is doing what in a combination
🧪5
REDEFINE is the trial
underwhelming honestly
back after 19 months, is monotherapy still a minority thing here
is there a reason people titrate this over more weeks than the others
💀4😂11📈4